Influence of venovenous extracorporeal membrane oxygenation on pharmacokinetics of vancomycin in lung transplant recipients

The influence of venovenous extracorporeal membrane oxygenation (VV‐ECMO) on the population pharmacokinetics (PPK) of vancomycin in recipients after lung transplantation (LTx) is unknown. We investigated whether VV‐ECMO influences vancomycin PPK and determined optimal recommended dosage for patients after LTx.

[1]  D. Tibboel,et al.  Drug Disposition and Pharmacotherapy in Neonatal ECMO: From Fragmented Data to Integrated Knowledge , 2019, Front. Pediatr..

[2]  Jeffrey M. Steele,et al.  Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia. , 2018, International journal of antimicrobial agents.

[3]  M. Rybak,et al.  Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin , 2017, Antimicrobial Agents and Chemotherapy.

[4]  A. Sieg,et al.  Evaluation of Altered Drug Pharmacokinetics in Critically Ill Adults Receiving Extracorporeal Membrane Oxygenation , 2017, Pharmacotherapy.

[5]  Jennifer Sherwin,et al.  Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature. , 2016, Clinical therapeutics.

[6]  W. Ko,et al.  Pharmacokinetics of vancomycin in adults receiving extracorporeal membrane oxygenation. , 2016, Journal of the Formosan Medical Association = Taiwan yi zhi.

[7]  J. Fraser,et al.  Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study , 2015, Critical Care.

[8]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods , 2013, CPT: pharmacometrics & systems pharmacology.

[9]  Kiran Shekar,et al.  ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO , 2012, BMC Anesthesiology.

[10]  D. Tibboel,et al.  The effect of inflammation on drug metabolism: a focus on pediatrics. , 2011, Drug discovery today.

[11]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  D. Tibboel,et al.  Determinants of drug absorption in different ECMO circuits , 2010, Intensive Care Medicine.

[13]  J. Roberts,et al.  Pharmacokinetic issues for antibiotics in the critically ill patient , 2009, Critical care medicine.

[14]  H. Mulla,et al.  Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. , 2005, British journal of clinical pharmacology.

[15]  Jerome J. Schentag,et al.  Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.

[16]  P. Gaehtgens,et al.  Leukocyte and Endothelial Activation in a Laboratory Model of Extracorporeal Membrane Oxygenation (ECMO) , 2000, Pediatric Research.

[17]  Jerome J. Schentag,et al.  Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[18]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .